Skip to main content

Tissue Regenix Group "has the opportunity to become a global commercial organisation"

Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) chief executive Danny Lee and chief financial officer David Cocke speak to Proactive's Thomas Warner after releasing a trading update for 2022. They reveal their highlights from the year before looking ahead to what investors can expect from the business during 2023. Lee says that Tissue Regenix "has the opportunity to become a global commercial organisation."

Contact Details

Proactive

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.86
+0.07 (0.03%)
AAPL  260.58
-3.77 (-1.43%)
AMD  203.37
+3.25 (1.62%)
BAC  52.77
-0.59 (-1.11%)
GOOG  303.56
-0.38 (-0.13%)
META  644.78
+1.56 (0.24%)
MSFT  398.46
-1.14 (-0.29%)
NVDA  187.90
-0.08 (-0.04%)
ORCL  156.54
+0.37 (0.24%)
TSLA  411.71
+0.39 (0.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.